617 related articles for article (PubMed ID: 32314731)
21. Identification of cyclophilin B-derived peptides capable of inducing histocompatibility leukocyte antigen-A2-restricted and tumor-specific cytotoxic T lymphocytes.
Tamura M; Nishizaka S; Maeda Y; Ito M; Harashima N; Harada M; Shichijo S; Itoh K
Jpn J Cancer Res; 2001 Jul; 92(7):762-7. PubMed ID: 11473727
[TBL] [Abstract][Full Text] [Related]
22. Immunodominance across HLA polymorphism: implications for cancer immunotherapy.
Kim CJ; Parkinson DR; Marincola F
J Immunother; 1998 Jan; 21(1):1-16. PubMed ID: 9456431
[TBL] [Abstract][Full Text] [Related]
23. Human CD8 and CD4 T cell epitopes of epithelial cancer antigens.
Sato N; Nabeta Y; Kondo H; Sahara H; Hirohashi Y; Kashiwagi K; Kanaseki T; Sato Y; Rong S; Hirai I; Kamiguchi K; Tamura Y; Matsuura A; Takahashi S; Torigoe T; Ikeda H
Cancer Chemother Pharmacol; 2000; 46 Suppl():S86-90. PubMed ID: 10950155
[TBL] [Abstract][Full Text] [Related]
24. Retrovirally transduced human dendritic cells can generate T cells recognizing multiple MHC class I and class II epitopes from the melanoma antigen glycoprotein 100.
Lapointe R; Royal RE; Reeves ME; Altomare I; Robbins PF; Hwu P
J Immunol; 2001 Oct; 167(8):4758-64. PubMed ID: 11591807
[TBL] [Abstract][Full Text] [Related]
25. Targeting of cancer neoantigens with donor-derived T cell receptor repertoires.
Strønen E; Toebes M; Kelderman S; van Buuren MM; Yang W; van Rooij N; Donia M; Böschen ML; Lund-Johansen F; Olweus J; Schumacher TN
Science; 2016 Jun; 352(6291):1337-41. PubMed ID: 27198675
[TBL] [Abstract][Full Text] [Related]
26. Frequent occurrence of high affinity T cells against MELOE-1 makes this antigen an attractive target for melanoma immunotherapy.
Godet Y; Desfrançois J; Vignard V; Schadendorf D; Khammari A; Dreno B; Jotereau F; Labarrière N
Eur J Immunol; 2010 Jun; 40(6):1786-94. PubMed ID: 20217862
[TBL] [Abstract][Full Text] [Related]
27. Identification of HLA-A*03, A*11 and B*07-restricted melanoma-associated peptides that are immunogenic in vivo by vaccine-induced immune response (VIIR) analysis.
Reynolds SR; Celis E; Sette A; Oratz R; Shapiro RL; Johnston D; Fotino M; Bystryn JC
J Immunol Methods; 2000 Oct; 244(1-2):59-67. PubMed ID: 11033019
[TBL] [Abstract][Full Text] [Related]
28. Melan-A/MART-1-specific CD4 T cells in melanoma patients: identification of new epitopes and ex vivo visualization of specific T cells by MHC class II tetramers.
Bioley G; Jandus C; Tuyaerts S; Rimoldi D; Kwok WW; Speiser DE; Tiercy JM; Thielemans K; Cerottini JC; Romero P
J Immunol; 2006 Nov; 177(10):6769-79. PubMed ID: 17082590
[TBL] [Abstract][Full Text] [Related]
29. Identification of an HLA-DPB1*0501 restricted Melan-A/MART-1 epitope recognized by CD4+ T lymphocytes: prevalence for immunotherapy in Asian populations.
Meng Z; Wang Y; Zhang G; Ke Y; Yan Y; Wu L; Huang Q; Zeng G; Wang Y; Ying H; Jiao S
J Immunother; 2011 Sep; 34(7):525-34. PubMed ID: 21760531
[TBL] [Abstract][Full Text] [Related]
30. Functional analysis of tumor-specific Th cell responses detected in melanoma patients after dendritic cell-based immunotherapy.
Schultz ES; Schuler-Thurner B; Stroobant V; Jenne L; Berger TG; Thielemanns K; van der Bruggen P; Schuler G
J Immunol; 2004 Jan; 172(2):1304-10. PubMed ID: 14707109
[TBL] [Abstract][Full Text] [Related]
31. Identification of NY-ESO-1 epitopes presented by human histocompatibility antigen (HLA)-DRB4*0101-0103 and recognized by CD4(+) T lymphocytes of patients with NY-ESO-1-expressing melanoma.
Jäger E; Jäger D; Karbach J; Chen YT; Ritter G; Nagata Y; Gnjatic S; Stockert E; Arand M; Old LJ; Knuth A
J Exp Med; 2000 Feb; 191(4):625-30. PubMed ID: 10684854
[TBL] [Abstract][Full Text] [Related]
32. Direct identification of human tumor-associated peptide antigens and a preclinical model to evaluate their use.
Engelhard VH; Bullock TN; Colella TA; Mullins DW
Cancer J; 2000 May; 6 Suppl 3():S272-80. PubMed ID: 10874498
[TBL] [Abstract][Full Text] [Related]
33. Immunogenicity of the ALLAVGATK (gp100[17-25]) peptide in HLA-A3.1 melanoma patients.
Castelli C; Mazzocchi A; Rini F; Tarsini P; Rivoltini L; Maio M; Gallino G; Belli F; Parmiani G
Eur J Immunol; 1998 Apr; 28(4):1143-54. PubMed ID: 9565353
[TBL] [Abstract][Full Text] [Related]
34. Identification of multiple HLA-DR-restricted epitopes of the tumor-associated antigen CAMEL by CD4+ Th1/Th2 lymphocytes.
Slager EH; van der Minne CE; Krüse M; Krueger DD; Griffioen M; Osanto S
J Immunol; 2004 Apr; 172(8):5095-102. PubMed ID: 15067093
[TBL] [Abstract][Full Text] [Related]
35. Characterization of T-cell receptors directed against HLA-A*01-restricted and C*07-restricted epitopes of MAGE-A3 and MAGE-A12.
Zhu S; Van den Eynde BJ; Coulie PG; Li YF; El-Gamil M; Rosenberg SA; Robbins PF
J Immunother; 2012; 35(9):680-8. PubMed ID: 23090077
[TBL] [Abstract][Full Text] [Related]
36. Identification of human melanoma peptides recognized by class I restricted tumor infiltrating T lymphocytes.
Storkus WJ; Zeh HJ; Maeurer MJ; Salter RD; Lotze MT
J Immunol; 1993 Oct; 151(7):3719-27. PubMed ID: 7690811
[TBL] [Abstract][Full Text] [Related]
37. Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression.
Kawakami Y; Eliyahu S; Jennings C; Sakaguchi K; Kang X; Southwood S; Robbins PF; Sette A; Appella E; Rosenberg SA
J Immunol; 1995 Apr; 154(8):3961-8. PubMed ID: 7706734
[TBL] [Abstract][Full Text] [Related]
38. Tumor-reactive, SSX-2-specific CD8+ T cells are selectively expanded during immune responses to antigen-expressing tumors in melanoma patients.
Ayyoub M; Rimoldi D; Guillaume P; Romero P; Cerottini JC; Valmori D; Speiser D
Cancer Res; 2003 Sep; 63(17):5601-6. PubMed ID: 14500401
[TBL] [Abstract][Full Text] [Related]
39. Identification of known and novel immunogenic T-cell epitopes from tumor antigens recognized by peripheral blood T cells from patients responding to IL-2-based treatment.
Scheibenbogen C; Sun Y; Keilholz U; Song M; Stevanovic S; Asemissen AM; Nagorsen D; Thiel E; Rammensee HG; Schadendorf D
Int J Cancer; 2002 Mar; 98(3):409-14. PubMed ID: 11920592
[TBL] [Abstract][Full Text] [Related]
40. Epitope and HLA-type independent monitoring of antigen-specific T-cells after treatment with dendritic cells presenting full-length tumor antigens.
Van Nuffel AM; Tuyaerts S; Benteyn D; Wilgenhof S; Corthals J; Heirman C; Neyns B; Thielemans K; Bonehill A
J Immunol Methods; 2012 Mar; 377(1-2):23-36. PubMed ID: 22269772
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
